Stables G, Lawrence C M
Leeds General Infirmary, Leeds, UK.
Clin Exp Dermatol. 2002 Sep;27(6):432-5. doi: 10.1046/j.1365-2230.2002.01097.x.
An increasing number of patients who require surgical treatment for skin tumours also take anticoagulants or anti-platelet drugs to prevent thromboembolic events. Stopping therapy places the patient at risk from a thromboembolic event, whilst continuing treatment places them at risk from bleeding complications during surgery. We have reviewed all of the published studies of the effects of warfarin, aspirin, non-steroidal anti-inflammatory and other anti-platelet drugs on surgical outcome in patients having skin surgical procedures. There is little evidence that continuing with treatment is harmful in any of these groups with the exception of warfarin therapy, where the risk of haemorrhagic complications is presumably dependent on the degree of anticoagulation.
越来越多需要接受皮肤肿瘤手术治疗的患者同时服用抗凝剂或抗血小板药物以预防血栓栓塞事件。停止治疗会使患者面临血栓栓塞事件的风险，而继续治疗则会使他们在手术期间面临出血并发症的风险。我们回顾了所有已发表的关于华法林、阿司匹林、非甾体抗炎药和其他抗血小板药物对接受皮肤外科手术患者手术结果影响的研究。几乎没有证据表明，除华法林治疗外，继续使用这些药物对任何一组患者有害，而华法林治疗出血并发症的风险可能取决于抗凝程度。
